Cialis vs Viagra: What to Do When One Fails

Why PDE5 Inhibitors Fail in the First Place

Before deciding to switch, you need to know why the drug you're currently on is not producing results. Failure falls into two broad categories: pseudo-failure caused by incorrect use, and true pharmacological failure caused by disease severity or pharmacokinetics. Identifying which category applies to you determines the correct next step.

Pseudo-Failure: The Most Common Reason

Pseudo-failure accounts for a substantial proportion of men who report that "the pill didn't work." In a frequently cited analysis, up to 50% of men who reported PDE5 inhibitor failure had never taken the medication correctly, either without adequate sexual stimulation, too close to a heavy meal (critical for sildenafil), or at a subtherapeutic dose [1].

Sildenafil's absorption is reduced by approximately 29% when taken with a high-fat meal, directly lowering peak plasma concentration [2]. Tadalafil is not meaningfully affected by food, which is one reason some men find it more reliable in real-world conditions.

Common pseudo-failure triggers:

• Taking sildenafil within 30 minutes of a fatty meal
• Not waiting the full 30 to 60 minutes before sexual activity
• Attempting intercourse without sufficient arousal
• Using the lowest starting dose (25 mg sildenafil or 5 mg on-demand tadalafil) when a higher dose may be needed
• Taking only one dose and concluding the drug does not work (guidelines recommend 6 to 8 attempts at an optimized dose before declaring failure) [3]

True Pharmacological Failure

True failure occurs when the drug has been used correctly at its maximum approved dose across at least six to eight attempts and produces no clinically meaningful erection. This pattern is more common in men with severe arteriogenic ED, post-radical-prostatectomy ED, or poorly controlled diabetes [4].

In these cases, the endothelial damage is extensive enough that even maximal nitric-oxide-pathway amplification cannot produce sufficient cavernosal blood flow. Switching to the other PDE5 inhibitor alone is unlikely to resolve the problem, and adjunct therapy (penile rehabilitation, vacuum erection devices, intracavernosal alprostadil, or surgical referral) should be discussed.

Sildenafil (Viagra): What the Trial Data Actually Show

Sildenafil was the first approved oral ED therapy in the United States, receiving FDA approval in March 1998. The landmark phase-III data published by Goldstein et al. In the New England Journal of Medicine demonstrated that sildenafil produced improved erections in 69% of men across all doses versus 22% on placebo [1].

Dose Range and Titration

Sildenafil is approved at 25 mg, 50 mg, and 100 mg taken on demand. The standard starting dose is 50 mg. Men who show partial response at 50 mg should be titrated to 100 mg before concluding failure, the 100 mg dose produces roughly a 20-percentage-point improvement in International Index of Erectile Function (IIEF) scores compared with 25 mg [1].

Food and Timing Constraints

The food interaction is the most clinically significant practical limitation of sildenafil. High-fat meals delay peak plasma concentration (Tmax) from approximately 1 hour to 2 hours and reduce Cmax by 29% [2]. For men who typically have dinner before intimacy, this is a structural disadvantage relative to tadalafil.

Sildenafil should be taken on an empty stomach or after a low-fat snack, 45 to 60 minutes before anticipated activity. This scheduling requirement is manageable for some men but feels clinical and new for others, a real-world factor that drives non-adherence and pseudo-failure.

Side-Effect Profile

The most frequently reported adverse effects of sildenafil are headache (16%), flushing (10%), dyspepsia (7%), and transient blue-tinge visual disturbance (3%) caused by mild PDE6 inhibition in retinal photoreceptors [2]. Visual side effects are sildenafil-specific and are not seen with tadalafil.

Tadalafil (Cialis): Duration, Daily Dosing, and Where It Differs

Tadalafil received FDA approval in November 2003. Brock et al. Published one of the key efficacy trials in the Journal of Urology in 2002, showing that tadalafil 20 mg improved IIEF erectile function domain scores by 7.6 points over placebo and produced successful intercourse in 75% of attempts versus 32% for placebo [4].

The 36-hour duration of action is the most distinctive pharmacological feature of tadalafil. The plasma half-life of tadalafil is 17.5 hours versus 3 to 5 hours for sildenafil [5]. This extended window removes the timing pressure that many men find psychologically burdensome with sildenafil.

On-Demand vs. Daily Dosing

Tadalafil is unique among approved PDE5 inhibitors in having an FDA-approved daily low-dose regimen: 2.5 mg or 5 mg taken once daily regardless of planned sexual activity. This produces steady-state plasma levels that allow for spontaneous sexual activity at any time [5].

Daily tadalafil 5 mg is also FDA-approved for benign prostatic hyperplasia (BPH) with or without concurrent ED, making it the preferred option for men managing both conditions [5]. Men on daily tadalafil for BPH who experience inadequate ED response can have the dose confirmed at 5 mg before any switch is considered.

Side-Effect Profile

Tadalafil shares headache (11%) and flushing (4%) with sildenafil, but the rates are somewhat lower. Myalgia and back pain are tadalafil-specific, occurring in roughly 5 to 6% of users, attributed to PDE11 inhibition in skeletal and smooth muscle [4]. These effects are typically mild and resolve within 48 hours. Tadalafil has no clinically significant interaction with food or alcohol at moderate intake levels.

Head-to-Head Comparison: Tadalafil vs. Sildenafil

Direct comparison trials show similar efficacy between the two drugs when both are used at optimal doses and under optimal conditions. A Cochrane review of PDE5 inhibitors found that both agents produced IIEF erectile function domain improvements of 6 to 8 points over placebo, with no statistically significant between-drug difference in efficacy for the general ED population [6].

Where the drugs differ is in patient preference, not raw efficacy numbers.

Preference Data

In crossover preference studies where men used both drugs under standardized conditions, tadalafil is preferred by approximately 60 to 70% of participants, primarily because of the longer window and the absence of food restrictions [7]. This preference advantage does not mean tadalafil is pharmacologically superior. It means the pharmacokinetics of tadalafil fit the lifestyle of most men more comfortably.

Men who prefer sildenafil tend to cite its shorter duration (they do not want an effect persisting through the next day) or a more pronounced subjective "onset sensation." Sildenafil also has a lower cost per dose as a generic, which matters for men paying out of pocket.

The Drug-Drug Comparison Table

| Feature | Sildenafil (Viagra) | Tadalafil (Cialis) | |---|---|---| | Onset | 30 to 60 min | 30 to 60 min | | Duration | 4 to 6 hours | Up to 36 hours | | Half-life | 3 to 5 hours | 17.5 hours | | Food effect | Significant (high-fat reduces Cmax 29%) | Minimal | | Daily dosing option | No | Yes (2.5 mg, 5 mg) | | Visual side effects | Yes (blue tinge, 3%) | No | | Myalgia/back pain | Rare | 5 to 6% | | BPH indication | No | Yes | | Generic available | Yes | Yes |

When and How to Switch From One to the Other

Switching is appropriate when a patient has completed an adequate trial, defined as at least six to eight attempts at the maximum tolerated dose with correct administration, and has persistent ED scoring below 22 on the IIEF erectile function domain [3].

The following decision framework outlines the clinical pathway:

Step 1. Confirm the current drug was used correctly. Review timing relative to food, dose used, number of attempts, and adequacy of sexual stimulation. If any of these were suboptimal, optimize before switching.

Step 2. Maximize the current dose. If the patient is on sildenafil 50 mg with partial response, move to 100 mg for a minimum of four more attempts. If on tadalafil 10 mg on demand, move to 20 mg. If on daily tadalafil 2.5 mg, move to 5 mg.

Step 3. Assess for undertreated comorbidities. Testosterone deficiency, hypogonadism, uncontrolled diabetes, or hypertension can blunt PDE5 inhibitor response. The AUA 2018 ED Guideline states: "Optimization of modifiable risk factors and medical comorbidities before or concurrent with ED treatment is strongly recommended" [3]. A morning total testosterone level should be obtained in any man with persistent ED on a PDE5 inhibitor.

Step 4. Make the switch. If sildenafil failed: start tadalafil 10 mg on demand (or 5 mg daily) and titrate to 20 mg after four attempts if needed. Counsel the patient explicitly on the 36-hour window and the absence of food restrictions. Remind the patient that the drug still requires sexual stimulation to work.

If tadalafil failed: start sildenafil 50 mg on demand and counsel specifically on the food timing requirement. Titrate to 100 mg after four attempts if 50 mg produces only partial response.

Step 5. Set realistic expectations. Approximately 60 to 70% of men who switch after failing the first PDE5 inhibitor will respond to the second [7]. Men who fail both drugs at maximum doses under optimal conditions are candidates for second-line therapy (intracavernosal injection, vacuum erection device) or surgical evaluation.

Special Populations and Dose Adjustments

Post-Prostatectomy ED

Men with ED following radical prostatectomy represent one of the most challenging populations for PDE5 inhibitors. The cavernous nerve injury disrupts the primary nitric oxide signaling pathway that PDE5 inhibitors depend on. In nerve-sparing procedures, sildenafil 100 mg produces successful intercourse in approximately 43% of bilateral nerve-sparing patients versus 15% of non-nerve-sparing patients [1].

Daily low-dose tadalafil 5 mg has been studied as a penile rehabilitation strategy after prostatectomy. Data from a 9-month randomized trial showed that nightly tadalafil 5 mg preserved smooth-muscle content in cavernosal biopsy samples compared with on-demand dosing, though functional recovery rates at 9 months were not statistically different between groups [8].

Diabetes and Cardiovascular Disease

Men with type 2 diabetes have a two-to-threefold higher prevalence of ED compared with age-matched men without diabetes [9]. PDE5 inhibitor response rates are lower in this group, with sildenafil producing a successful erection in approximately 56% of diabetic men versus 69 to 82% in the general ED population [1].

Both tadalafil and sildenafil are safe to use in stable cardiovascular disease. The Princeton III Consensus recommends PDE5 inhibitors for men in the low-risk cardiovascular category without restriction and recommends cardiac risk stratification before prescribing in intermediate-risk patients [10]. The absolute contraindication shared by both drugs is concurrent nitrate use. The combination produces a pharmacodynamic interaction that can cause severe, potentially fatal hypotension [2].

Older Adults

Plasma clearance of sildenafil decreases by approximately 40% in men over age 65, resulting in higher plasma concentrations at a given dose [2]. Starting at 25 mg sildenafil or 5 mg on-demand tadalafil in men over 65 is prudent. Tadalafil clearance is similarly reduced in older men; dose adjustment to a maximum of 10 mg per 72 hours is recommended in patients with significant renal impairment (creatinine clearance <30 mL/min) [5].

What About Combination or Third-Line Options?

If both sildenafil and tadalafil fail at maximum doses under optimal conditions, several evidence-supported options exist before committing to surgical intervention.

Vardenafil (Levitra): A third PDE5 inhibitor with a selectivity profile slightly different from both sildenafil and tadalafil. Some men who fail sildenafil and tadalafil respond to vardenafil, though the absolute proportion is modest. A trial at 10 to 20 mg is reasonable [6].

Avanafil (Stendra): FDA-approved in 2012, avanafil has a faster onset (approximately 15 minutes) and higher PDE5 selectivity than sildenafil, reducing visual and back-pain side effects. It has not been directly compared with tadalafil in a large head-to-head trial, but it offers a pharmacological alternative for patients who experienced intolerable side effects from either first-line agent.

Intracavernosal alprostadil: Injection of alprostadil (prostaglandin E1) directly into the corpora cavernosa bypasses the nitric oxide pathway entirely and produces erections in approximately 70 to 80% of men regardless of nerve status [6]. It is second-line by convention rather than efficacy, the delivery method is the deterrent.

Testosterone replacement therapy (TRT): In men with documented hypogonadism (total testosterone <300 ng/dL on two morning measurements per AUA guidelines), TRT alone or added to a PDE5 inhibitor can restore adequate response. A meta-analysis of 7 randomized controlled trials found that testosterone supplementation significantly improved IIEF scores in hypogonadal men with ED [9].

Optimizing Lifestyle Factors That Affect Both Drugs

PDE5 inhibitors amplify nitric oxide signaling. The robustness of that amplification depends on how much endogenous nitric oxide capacity the patient has to begin with. Lifestyle factors that improve endothelial function directly improve PDE5 inhibitor response.

Exercise: A meta-analysis published in the Journal of Sexual Medicine found that aerobic exercise at moderate-to-vigorous intensity (at least 160 minutes per week) improved IIEF scores by 3.85 points, a clinically meaningful change, without any pharmacological intervention [11].

Smoking cessation: Cigarette smoking accelerates endothelial dysfunction. Men who stopped smoking showed significant improvement in erectile function within 1 year in prospective observational data [12].

Weight loss: Obesity is independently associated with ED. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% placebo [13]. While STEP-1 was not an ED trial, the degree of weight loss achieved with GLP-1 receptor agonists is associated with meaningful improvement in testosterone levels and erectile function in men with obesity.

Alcohol moderation: Moderate alcohol (one to two drinks) does not significantly interact with either drug. Heavy alcohol intake impairs the erection independent of the medication, generating another pseudo-failure scenario.